Comparative Pharmacology
Head-to-head clinical analysis: TARACTAN versus TRIFLUOPERAZINE HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TARACTAN versus TRIFLUOPERAZINE HCL.
TARACTAN vs TRIFLUOPERAZINE HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Trifluoperazine is a typical antipsychotic of the phenothiazine class. It acts primarily as a dopamine D2 receptor antagonist, blocking postsynaptic dopamine receptors in the mesolimbic and mesocortical pathways. It also exhibits moderate anticholinergic, antiadrenergic, and antihistaminergic activity.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
2-10 mg orally twice daily; maximum 40 mg/day. For severe psychosis, 5-20 mg intramuscularly every 4-6 hours, maximum 30 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
12-30 hours (terminal elimination half-life); clinical context: requires multiple daily dosing or extended-release formulations for steady-state maintenance.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Renal (as metabolites, less than 1% unchanged); fecal (biliary) elimination of metabolites accounts for a significant portion; total recovery in urine and feces accounts for >90% of a dose.
Category C
Category A/B
Typical Antipsychotic
Typical Antipsychotic